Genentech: Gina Xiaojing Wang | Senior Principal Scientist (Chemistry) and Director of Research, Discovery Chemistry, Drug Discovery

Scientists / Our Scientists

"Helping patients is my mission and innovation is the strategy. Innovating for life is especially meaningful and gratifying."

Years at Genentech

Publications at Genentech

Awards & Honors

I decided to join Genentech at 2006 as a scientist. What appealed me particularly to work at Genentech was the casual yet intense science-driven culture. Over the years, I led multiple disciplinary teams in driving projects towards deliveries into our pipeline of experimental therapies. It has been so much fun doing science together with super talented colleagues from all levels.

Today, I am a Principal Scientist and Project Team Lead, mentoring junior scientists and leading teams in discovering therapeutics of novel targets. What we are working on is often very challenging but we are fully motivated by patients who are waiting for breakthrough medicines.

Featured Publication

From Discovery to Bedside: Targeting the Ubiquitin System.

Cell Chem Biol. 2018 Nov 28. pii: S2451-9456(18)30382-9.

Wertz IE, Wang X.

View Abstract

Discovery of Potent and Selective Tricyclic Inhibitors of Bruton0s Tyrosine Kinase with Improved Druglike Properties.

ACS Med Chem Lett. 2017 May 3;8(6):608-613.

Wang X, Barbosa J, Blomgren P, Bremer MC, Chen J, Crawford JJ, Deng W, Dong L, Eigenbrot C, Gallion S, Hau J, Hu H, Johnson AR, Katewa A, Kropf JE, Lee SH, Liu L, Lubach JW, Macaluso J, Maciejewski P, Mitchell SA, Ortwine DF, DiPaolo J, Reif K, Scheerens H, Schmitt A, Wong H, Xiong JM, Xu J, Zhao Z, Zhou F, Currie KS, Young WB.

View Abstract

As a medicinal chemist, my focus is to invent novel therapeutic modalities for the treatment of various disease areas through hit identification and lead optimization integrating efficacy, pharmacokinetics and safety profile. The innovation includes new chemical matters and novel mode or mechanism of action. I am also interested in investigating tissue specific delivery to maximize safety margin of effective therapies.

Optimization of a Novel DEL Hit That Binds in the Cbl-b SH2 Domain and Blocks Substrate Binding

ACS Medicinal Chemistry Letters,

Jun Liang; Michael J. Lambrecht; Teresita L. Arenzana; Samuel Aubert-Nicol; Linda Bao; Broccatelli; Jianping Cai; Celine Eidenschenk; Christine Everett; Thomas Garner; Felix Gruber; Pouyan Haghshenas; Malcolm P. Huestis; Peter L. Hsu; Ponien Kou; Araz Jakalian; Larouche-Gauthier; Jean-Philippe Leclerc; Dennis H. Leung; Aaron Martin; Jeremy Murray; Madeleine S. Prangley; Sascha Rutz; Satoko Kakiuchi-Kiyota; Alexander Lee Satz; Nicholas J. Skelton; Micah Steffek; Daniel Stoffler; Jawahar Sudhamsu; Sophia Tan; Jian Wang; Shouliang Wang; Qiuyue Wang; Timothy J. Wendorff; Moreno Wichert; Arun Yadav; Christine Yu; Xiaojing Wang

Attention: This page may not render properly. The browser you are using, Internet Explorer 10, is no longer supported.

Gina Xiaojing Wang

Senior Principal Scientist (Chemistry) and Director of Research, Discovery Chemistry, Drug Discovery

Featured Publication

From Discovery to Bedside: Targeting the Ubiquitin System.

Discovery of Potent and Selective Tricyclic Inhibitors of Bruton0s Tyrosine Kinase with Improved Druglike Properties.